Skip to Content

Category: Eylea

In Europe, a New Radiation Therapy for Wet Macular Degeneration Reduces Need for Lucentis Injections

From: VisionAware Blog
Categories: Avastin , Clinical Trials , Eylea , Low Vision , Lucentis , Macular Degeneration , Medical Updates
By

Oraya Therapeutics, Inc. has released the results of its INTREPID clinical trial evaluating the safety and effectiveness of Oraya Therapy Stereotactic Radiotherapy for the treatment of wet age-related macular degeneration (AMD). The results indicate that a single dose of Oraya Therapy significantly reduces the need for Lucentis injections in persons with wet AMD, with positive … Continued

FDA Approves EYLEA™ for the Treatment of Wet Macular Degeneration

From: VisionAware Blog
Categories: Avastin , Clinical Trials , Eylea , Health , Low Vision , Lucentis , Macular Degeneration , Medical Updates
By

Anatomy of the EYLEA™ Drug Approval Process In February 2011, Regeneron Pharmaceuticals, Inc. announced that the company had submitted a Biologics License Application (BLA) to the United States Food and Drug Administration (FDA) for Regeneron’s VEGF Trap-Eye (now called EYLEA™), a potential injectable drug treatment for wet age-related macular degeneration (AMD). The FDA next announced … Continued